Will Weakness in Consun Pharmaceutical Group Limited's (HKG:1681) Stock Prove Temporary Given Strong Fundamentals?
Consun Pharmaceutical Group (HKG:1681) has had a rough week with its share price down 13%. However, stock prices are usually driven by a company's financial performance over the long term, which in
Consun Pharma recently exercised the purchase of equity to issue a total of about 1.5083 million shares.
Consun Pharma (01681) announced that from June 3 to June 6, 2024, it will exercise the option to purchase equity and issue a total of approximately 1.5083 million shares.
Consun Pharma (01681) recently exercised its purchase of equity rights and issued approximately 1.5083 million shares.
Consun Pharma (01681) announced that from June 3 to June 6, 2024, it will exercise a total of approximately 15... million shares for the acquisition of equity.
CONSUN PHARMA To Go Ex-Dividend On June 11th, 2024 With 0.3 HKD Dividend Per Share And 0.3 HKD Special Dividend Per Share
May 31st - $CONSUN PHARMA(01681.HK)$ is trading ex-dividend on June 11th, 2024. Shareholders of record on June 12th, 2024 will receive 0.3 HKD dividend per share and 0.3 HKD special dividend per s
Consun Pharmaceutical Group Announces Special Dividend on 10th Anniversary of Joining HK Bourse
Consun Pharmaceutical Group (HKG:1681) announced a special dividend of HK$0.3 per share on the tenth anniversary of listing the company's shares on the Hong Kong Stock Exchange, according to a Friday
Kangchen Pharmaceutical (01681.HK): Proposes to declare a special dividend of HK$0.3 per share
Gelonghui, May 24, 丨 Kangchen Pharmaceutical (01681.HK) announced that to celebrate the 10th anniversary of the listing of the company's shares on the main board of the Hong Kong Stock Exchange Limited and to thank the company's shareholders for their long-term support, the board of directors is pleased to announce that it has decided to declare a special dividend of HK$0.3 per share and pay it to shareholders listed in the company's shareholder register at the end of business hours on June 12, 2024 (Wednesday) (record date). The special dividend is expected to be paid in HKD on or around June 21, 2024 (Friday). To ensure eligibility for the special dividend, all duly completed transfer forms are accompanied by the relevant
康臣葯業:宣派特別股息
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
CONSUN PHARMA: CLARIFICATION ANNOUNCEMENT
Changes in Hong Kong stocks | Kangchen Pharmaceutical (01681) rose more than 6% and plans to review the special dividend issuance next Friday. The company's profit double increased last year
Kangchen Pharmaceutical (01681) rose more than 6%. As of press release, it rose 6.43% to HK$6.95, with a turnover of HK$10.996 million.
Insiders Were the Key Beneficiaries as Consun Pharmaceutical Group Limited's (HKG:1681) Market Cap Rises to HK$5.2b
Key Insights Consun Pharmaceutical Group's significant insider ownership suggests inherent interests in company's expansion A total of 3 investors have a majority stake in the company with 57% owner
Kangchen Pharmaceutical (01681.HK) plans to hold a board meeting on May 24 to review and approve the special dividend announcement
Glonghui, May 13, 丨 Kangchen Pharmaceutical (01681.HK) announced that the company will hold a board meeting on May 24, 2024 (Friday) to review and approve the issuance of special dividends and handle any other business (if any): if approved by the board of directors, the company will publish the company separately after the board meeting to include details of the special dividend.
Consun Pharmaceutical to Grant About 8.2 Million Share Options Under New Program
Consun Pharmaceutical Group (HKG:1681) plans to grant share options of about 8.2 million shares, representing 10% of the company's total issued shares, according to a Tuesday filing on the Hong Kong b
康臣葯業:股東周年大會通告
康臣葯業:2023 年度報告
Kangchen Pharmaceutical (01681) Annual Report View: A high-dividend pharmaceutical company with steady performance, rich products, and double revenue and profit
In 2023, Kangchen Pharmaceutical continued the steady growth trend of performance, achieving operating income of 2.59 billion yuan (unit, same below), up 10.7% year on year; gross profit of 1.92 billion yuan, up 9.0% year on year; gross margin of 74.2%; and net profit to mother of 785 million yuan, up 14.9% year on year.
Keep integrity, innovate, and go farway丨Understand Kangchen Pharmaceutical (1681.HK)'s 2023 performance in one picture
Recently, Kangchen Pharmaceutical (1681.HK), the market leader in proprietary Chinese medicines for nephropathy, announced the results for the year ended December 31, 2023. The following will show you the 2023 annual results of Kangson Pharmaceuticals through a chart.
Consun Pharmaceutical Group Sees 15% Increase in 2023 Profit
Consun Pharmaceutical Group (HKG:1681) posted a 2023 profit attributable to shareholders of 784.5 million yuan, or 0.98 yuan per share, up from 682.9 million yuan, or 0.86 yuan per share, a year earli
Conson Pharmaceutical (01681) proposes to adopt the 2024 share option plan
Zhitong Finance App News, Kangchen Pharmaceutical (01681) issued an announcement. The company adopted the 2013 share purchase plan on December 2, 2013. According to the terms of the 2013 Share Option Plan, unless otherwise terminated or amended, the 2013 Share Option Plan will be valid for 10 years from the date of its adoption and will expire on December 1, 2023. After the 2013 share option plan expires, no share options will be offered or granted. As of the date of this announcement, there were still 504.63,900 share options granted but not yet exercised in the 2013 share option plan. In view of the 2013 share option plan
Kangchen Pharmaceutical (01681.HK): Net profit increased by 14.9% in 2023 to reach $780 million with final interest of HK$0.3 per share
On March 28, Ge Longhui | Kangchen Pharmaceutical (01681.HK) announced that in 2023, the Group achieved sales revenue of about RMB 2.59 billion, an increase of about 10.7% over the previous year; profit attributable to the company's equity shareholders was approximately RMB 780 million, an increase of about 14.9% over the previous year. Basic and diluted earnings per share were approximately RMB 0.99 and RMB 0.98 respectively. The Board proposed a final dividend of HK$0.3 per share for the year 2023. Looking at the business segment, Kangchen Pharmaceutical's sales revenue in 2023 was about RMB 2.2 billion, an increase of about 1 percent over the previous year
No Data